Kisspeptin-54 Restores Blood-Brain Barrier Integrity via GATA-4 in Ischemic Stroke.

Shan W, Lan H, Wu Y, Xu Q, You M, Ma R

Chemical biology & drug design1 Jun 2025Cited by 2 (Europe PMC)

PMID40454669DOI10.1111/cbdd.70134PepBankPUB-40454669

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with middle cerebral artery occlusion, prophylactic Kisspeptin‑54 reduced cerebral infarct volume by 42%.
In plain wordsIn mice with stroke, Kisspeptin‑54 given beforehand reduced the size of the brain damage by 42%.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseCerebral infarct volume
Study
mousen: not reported in source
middle cerebral artery occlusion (MCAO)
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Infarct volume reduction
42%
prophylactic Kisspeptin-54
Source sentences
Summary
Prophylactic Kisspeptin-54 reduced cerebral infarct volume by 42%
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, mice underwent middle cerebral artery occlusion (MCAO), and cerebral infarct volume, neurological function, and blood-brain barrier (BBB) permeability were evaluated.
Report a problemFND-4045466904
02AnimalAnimal study (in vivo)Efficacy outcome
In mice with middle cerebral artery occlusion, prophylactic Kisspeptin‑54 enhanced neurological performance by 49%.
In plain wordsIn mice with stroke, Kisspeptin‑54 given beforehand improved nerve function scores by 49%.
Peptide
Kisspeptin-54 (metastin)
Outcome
IncreaseNeurological performance
Study
mousen: not reported in source
middle cerebral artery occlusion (MCAO)
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Neurological performance improvement
49%
prophylactic Kisspeptin-54
Source sentences
Summary
Prophylactic Kisspeptin-54 reduced cerebral infarct volume by 42%, enhanced neurological performance by 49%
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, mice underwent middle cerebral artery occlusion (MCAO), and cerebral infarct volume, neurological function, and blood-brain barrier (BBB) permeability were evaluated.
Report a problemFND-4045466905
03AnimalAnimal study (in vivo)Efficacy outcome
In mice with middle cerebral artery occlusion, prophylactic Kisspeptin‑54 decreased blood-brain barrier leakage by 26%.
In plain wordsIn mice with stroke, Kisspeptin‑54 given beforehand reduced leakage across the blood-brain barrier by 26%.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseBlood-brain barrier leakage
Study
mousen: not reported in source
middle cerebral artery occlusion (MCAO)
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Measurements
BBB leakage reduction
26%
prophylactic Kisspeptin-54
Source sentences
Summary
Prophylactic Kisspeptin-54 reduced cerebral infarct volume by 42%, enhanced neurological performance by 49%, and decreased BBB leakage by 26%
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, mice underwent middle cerebral artery occlusion (MCAO), and cerebral infarct volume, neurological function, and blood-brain barrier (BBB) permeability were evaluated.
Report a problemFND-4045466906
04AnimalAnimal study (in vivo)Efficacy outcome
In mice with middle cerebral artery occlusion, prophylactic Kisspeptin‑54 produced near-complete occludin recovery.
In plain wordsIn mice with stroke, Kisspeptin‑54 given beforehand nearly restored occludin, a barrier protein.
Peptide
Kisspeptin-54 (metastin)
Outcome
IncreaseOccludin recovery
Study
mousen: not reported in source
middle cerebral artery occlusion (MCAO)
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
with near-complete occludin recovery.
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, mice underwent middle cerebral artery occlusion (MCAO), and cerebral infarct volume, neurological function, and blood-brain barrier (BBB) permeability were evaluated.
Report a problemFND-4045466907
05LabIn vitro (cells)Efficacy outcome
In HBMVECs exposed to oxygen-glucose deprivation/reperfusion, Kisspeptin‑54 reduced paracellular flux by 48%.
In plain wordsIn cells, Kisspeptin‑54 reduced leakage between brain blood vessel cells by 48%.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseParacellular flux
Study
humann: not reported in source
human brain microvascular endothelial cells (HBMVECs) exposed to oxygen-glucose deprivation/reperfusion
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Paracellular flux reduction
48%
HBMVECs
Source sentences
Summary
In vitro: Kisspeptin-54 treatment reduced paracellular flux by 48% and increased transendothelial resistance by 60%.
1 context sentence(design, population, supporting numbers)
Summary · context
In vitro, human brain microvascular endothelial cells (HBMVECs) were exposed to oxygen-glucose deprivation/reperfusion (OGD/R) to assess the effects of Kisspeptin-54 on paracellular flux and transendothelial electrical resistance (TEER).
Report a problemFND-4045466908
06LabIn vitro (cells)Efficacy outcome
In HBMVECs exposed to oxygen-glucose deprivation/reperfusion, Kisspeptin‑54 increased transendothelial resistance by 60%.
In plain wordsIn cells, Kisspeptin‑54 strengthened a brain blood vessel cell barrier, with 60% higher resistance.
Peptide
Kisspeptin-54 (metastin)
Outcome
IncreaseTransendothelial electrical resistance
Study
humann: not reported in source
human brain microvascular endothelial cells (HBMVECs) exposed to oxygen-glucose deprivation/reperfusion
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Transendothelial resistance increase
60%
HBMVECs
Source sentences
Summary
In vitro: Kisspeptin-54 treatment reduced paracellular flux by 48% and increased transendothelial resistance by 60%.
1 context sentence(design, population, supporting numbers)
Summary · context
In vitro, human brain microvascular endothelial cells (HBMVECs) were exposed to oxygen-glucose deprivation/reperfusion (OGD/R) to assess the effects of Kisspeptin-54 on paracellular flux and transendothelial electrical resistance (TEER).
Report a problemFND-4045466909

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

07AnimalEndogenous levelAnimal study (in vivo)Mechanism
In mice with middle cerebral artery occlusion, cortical ischemia downregulated KISS1 mRNA.
In plain wordsIn mice with stroke, the gene for the body's own kisspeptin was less active in the brain cortex.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseKISS1 mRNA after cortical ischemia
Study
mousen: not reported in source
middle cerebral artery occlusion (MCAO)
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
KISS1 mRNA reduction
59%
cortical ischemia
Source sentences
Summary
cortical ischemia downregulated KISS-1 metastasis-suppressor (KISS1, 59% mRNA; 55% protein)
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, mice underwent middle cerebral artery occlusion (MCAO), and cerebral infarct volume, neurological function, and blood-brain barrier (BBB) permeability were evaluated.
This result measures the body's own Kisspeptin-54 (metastin). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4045466901
08AnimalEndogenous levelAnimal study (in vivo)Mechanism
In mice with middle cerebral artery occlusion, cortical ischemia downregulated KISS1 protein.
In plain wordsIn mice with stroke, the body's own kisspeptin protein was lower in the brain cortex.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseKISS1 protein after cortical ischemia
Study
mousen: not reported in source
middle cerebral artery occlusion (MCAO)
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
KISS1 protein reduction
55%
cortical ischemia
Source sentences
Summary
cortical ischemia downregulated KISS-1 metastasis-suppressor (KISS1, 59% mRNA; 55% protein)
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, mice underwent middle cerebral artery occlusion (MCAO), and cerebral infarct volume, neurological function, and blood-brain barrier (BBB) permeability were evaluated.
This result measures the body's own Kisspeptin-54 (metastin). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4045466902
09AnimalEndogenous levelAnimal study (in vivo)Mechanism
In mice with middle cerebral artery occlusion, circulating Kisspeptin‑54 declined by 32%.
In plain wordsIn mice with stroke, the body's own Kisspeptin‑54 in the blood was lower.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseCirculating Kisspeptin-54 after cortical ischemia
Study
mousen: not reported in source
middle cerebral artery occlusion (MCAO)
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
Circulating Kisspeptin-54 decline
32%
cortical ischemia
Source sentences
Summary
with a 32% decline in circulating Kisspeptin-54.
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, mice underwent middle cerebral artery occlusion (MCAO), and cerebral infarct volume, neurological function, and blood-brain barrier (BBB) permeability were evaluated.
This result measures the body's own Kisspeptin-54 (metastin). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4045466903

Studies that did not test the peptide alone3

In this study, Kisspeptin-54 (metastin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-54 (metastin).

10LabNot a test of Kisspeptin-54 (metastin) aloneIn vitro (cells)Mechanism
In HBMVECs, GATA-4 silencing abolished Kisspeptin‑54-induced occludin restoration.
In plain wordsIn cells, silencing the GATA-4 gene stopped Kisspeptin‑54 from restoring occludin.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseKisspeptin-54-induced occludin restoration after GATA-4 silencing
Study
humann: not reported in source
human brain microvascular endothelial cells (HBMVECs) with GATA-4 silencing
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
GATA-4 silencing abolished Kisspeptin-54-induced occludin restoration, increasing permeability by 65% and diminishing barrier resistance by 28%.
1 context sentence(design, population, supporting numbers)
Summary · context
Additionally, GATA-4 was silenced to investigate its role in mediating protection.
In this study, Kisspeptin-54 (metastin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-54 (metastin).
Report a problemFND-4045466910
11LabNot a test of Kisspeptin-54 (metastin) aloneIn vitro (cells)Mechanism
In HBMVECs treated with Kisspeptin‑54, GATA-4 silencing increased permeability by 65%.
In plain wordsIn cells, silencing the GATA-4 gene increased barrier leakiness by 65% in the presence of Kisspeptin‑54.
Peptide
Kisspeptin-54 (metastin)
Outcome
IncreasePermeability after GATA-4 silencing with Kisspeptin-54
Study
humann: not reported in source
human brain microvascular endothelial cells (HBMVECs) with GATA-4 silencing
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Measurements
Permeability increase
65%
GATA-4 silencing
Source sentences
Summary
GATA-4 silencing abolished Kisspeptin-54-induced occludin restoration, increasing permeability by 65% and diminishing barrier resistance by 28%.
1 context sentence(design, population, supporting numbers)
Summary · context
Additionally, GATA-4 was silenced to investigate its role in mediating protection.
In this study, Kisspeptin-54 (metastin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-54 (metastin).
Report a problemFND-4045466911
12LabNot a test of Kisspeptin-54 (metastin) aloneIn vitro (cells)Mechanism
In HBMVECs treated with Kisspeptin‑54, GATA-4 silencing diminished barrier resistance by 28%.
In plain wordsIn cells, silencing the GATA-4 gene lowered barrier resistance by 28% in the presence of Kisspeptin‑54.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseBarrier resistance after GATA-4 silencing with Kisspeptin-54
Study
humann: not reported in source
human brain microvascular endothelial cells (HBMVECs) with GATA-4 silencing
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Measurements
Barrier resistance reduction
28%
GATA-4 silencing
Source sentences
Summary
GATA-4 silencing abolished Kisspeptin-54-induced occludin restoration, increasing permeability by 65% and diminishing barrier resistance by 28%.
1 context sentence(design, population, supporting numbers)
Summary · context
Additionally, GATA-4 was silenced to investigate its role in mediating protection.
In this study, Kisspeptin-54 (metastin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-54 (metastin).
Report a problemFND-4045466912

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.